G
G. Kiranmai
Researcher at University of Hyderabad
Publications - 4
Citations - 458
G. Kiranmai is an academic researcher from University of Hyderabad. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 403 citations.
Papers
More filters
Journal ArticleDOI
Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis.
TL;DR: The present study points out that the hepatoprotective, anti-inflammatory, and anti-arthritic properties of phycocyanin reported in the literature may be due, in part, to its selective COX-2 inhibitory property, although its ability to efficiently scavenge free radicals and effectively inhibit lipid peroxidation may also be involved.
Journal ArticleDOI
C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Madhava C. Reddy,Jagu Subhashini,Suraneni V.K. Mahipal,Vadiraja B. Bhat,P Srinivas Reddy,G. Kiranmai,K.M. Madyastha,Pallu Reddanna +7 more
TL;DR: This C-PC induced apoptosis in RAW 264.7 cells appears to be mediated by the release of cytochrome c from mitochondria and independent of Bcl-2 expression, and may be due to reduced PGE(2) levels as a result of COX-2 inhibition.
Journal ArticleDOI
Exploration of Mercaptoacetamide-linked Pyrimidine-1,3,4-Oxadiazole Derivatives as DNA Intercalative Topo II inhibitors: Cytotoxicity and Apoptosis Induction.
Arbaz Sujat Shaikh,G. Kiranmai,G. Parimala Devi,Priyanka N. Makhal,Dilep Kumar Sigalapalli,Ramya Tokala,Venkata Rao Kaki,Nagula Shankaraiah,Narayana Nagesh,Bathini Nagendra Babu,Neelima D. Tangellamudi +10 more
TL;DR: In this article , a new series of mercaptoacetamide-linked pyrimidine-1,3,4-oxadiazole hybrids was designed and synthesized, and the in vitro cytotoxic potential of these new compounds was evaluated against lung cancer (A549), prostate cancer (PC-3, DU-145) and human embryonic kidney (HEK) cell lines.
Journal ArticleDOI
A unique water soluble probe for measuring the cardiac marker homocysteine and its clinical validation.
Snehasish Debnath,Ratish R. Nair,Riya Ghosh,G. Kiranmai,N. Radhakishan,Narayana Nagesh,Pabitra B. Chatterjee +6 more
TL;DR: Results from clinical examination of cardiac samples by 1 when combined with the outcome of the reliability testing involving a clinically approved commercial immunoassay kit, validates the prospect of the molecular probe for direct measurement of Hcy in human plasma, which is unprecedented.